FOLH1 and prostate carcinoma: Duan et al. directly compared [68Ga]-P137 and [68Ga]-PSMA-617 PET/CT in three patients with prostate cancer who underwent both [68Ga]-P137 and [68Ga]-PSMA-617 PSMA PET within five days [13].